Hanaoka Masanori, Katsumata Yasuhiro, Kawasumi Hidenaga, Kawaguchi Yasushi, Yamanaka Hisashi
a Institute of Rheumatology , Tokyo Women's Medical University , Tokyo , Japan.
Mod Rheumatol. 2019 Jul;29(4):625-632. doi: 10.1080/14397595.2018.1553488. Epub 2019 Jan 8.
We aimed to evaluate the usefulness of serum KL-6 for interstitial lung disease (ILD) with polymyositis/dermatomyositis (PM/DM). All consecutive and previously untreated adult patients with PM/DM who were admitted to our hospital from 2010 to 2015 were included. The associations between serum KL-6 levels and clinical information were retrospectively analyzed. Baseline serum KL-6 levels were significantly higher in patients with ILD than in those without ( = 41 and 15, respectively; < .001). In the 14 patients whose ILD improved within 4 weeks post-treatment, their serum KL-6 levels did not significantly decrease at 2 weeks, 4 weeks, or 3 months post-treatment ( = 1.00, 1.00, and .83, respectively). Conversely, their serum KL-6 levels significantly decreased at 6, 9, and 12 months post-treatment ( = .01 in all comparisons). In the 12 patients whose ILD remained unchanged or deteriorated in 4 weeks post-treatment, only the difference between their serum KL-6 levels at 3 and 12 months was significant ( = .003). The present study validated the serum KL-6 as a diagnostic marker for ILD in PM/DM. However, serum KL-6 is not a short-term disease-activity biomarker for ILD with PM/DM, but it is a long-term disease-activity biomarker.
我们旨在评估血清KL-6在伴发多发性肌炎/皮肌炎（PM/DM）的间质性肺病（ILD）中的作用。纳入了2010年至2015年期间连续收治且此前未接受治疗的成年PM/DM患者。对血清KL-6水平与临床信息之间的关联进行了回顾性分析。ILD患者的基线血清KL-6水平显著高于无ILD者（分别为41例和15例；P<0.001）。在14例治疗后4周内ILD病情改善的患者中，其血清KL-6水平在治疗后2周、4周或3个月时未显著下降（P分别为1.00、1.00和0.83）。相反，其血清KL-6水平在治疗后6个月、9个月和12个月时显著下降（所有比较中P均为0.01）。在12例治疗后4周内ILD病情未改变或恶化的患者中，仅其血清KL-6水平在3个月和12个月时的差异具有显著性（P=0.003）。本研究验证了血清KL-6可作为PM/DM中ILD的诊断标志物。然而，血清KL-6并非伴发PM/DM的ILD的短期疾病活动生物标志物，而是一种长期疾病活动生物标志物。
